{"name":"Athenex, Inc.","slug":"athenex-inc","ticker":"","exchange":"","domain":"","description":"Athenex, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer. The company has a diverse pipeline of nine drug candidates, with a strong emphasis on oncology, and is particularly known for its innovative oral and intravenous formulations of paclitaxel.","hq":"","founded":0,"employees":"~500","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$0.2B","metrics":{"revenue":101229000,"revenueGrowth":13.6,"grossMargin":26.4,"rdSpend":51758000,"netIncome":-103427000,"cash":30437000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Oradoxel","genericName":"Oradoxel","slug":"oradoxel","indication":"Other","status":"phase_1"},{"name":"Oratecan","genericName":"Oratecan","slug":"oratecan","indication":"Other","status":"phase_1"},{"name":"Oratopo","genericName":"Oratopo","slug":"oratopo","indication":"Other","status":"phase_1"},{"name":"Oraxol","genericName":"Oraxol","slug":"oraxol","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IV paclitaxel","genericName":"IV paclitaxel","slug":"iv-paclitaxel","indication":"Metastatic breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"IV paclitaxel","genericName":"IV paclitaxel","slug":"iv-paclitaxel","phase":"phase_3","mechanism":"IV paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Ovarian cancer","Kaposi sarcoma"],"catalyst":""},{"name":"Oradoxel","genericName":"Oradoxel","slug":"oradoxel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oratecan","genericName":"Oratecan","slug":"oratecan","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oratopo","genericName":"Oratopo","slug":"oratopo","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oraxol","genericName":"Oraxol","slug":"oraxol","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2023-10-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-08-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQZ1psTjh1M21KOEpUNzlaZU16SXNyTDNvUWJvb3MzeHI3WUNTd3JnMlYtTlcyaGxYS2NtcGJTcXF6VDZhZ2dfZVZ4UUhhZXN5YkdBR3pyMEVEbGhWc1ZKVzFNTi1SdlRTSVp1ZWVYLWNnUV82ZzFON2ZsOXN5Uy14dXducUtUWWF2WXFtZlNQN0V6VWRvcWgxZTRTc3h0QXIwZG9ZSm1rZ25KOWVMQjNDYnZ2OU9HaXRvRERLQWFFOHBJbURac3J5ZmdGVTZGcUVxRTNodmpzUTJ1VkJPTHdyZHA5bUc?oc=5","date":"2023-07-31","type":"pipeline","source":"WGRZ","summary":"Athenex assets sold in bankruptcy auction; top executives dismissed - WGRZ","headline":"Athenex assets sold in bankruptcy auction; top executives dismissed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQYjVGY2ZlUHZkcy1qajNITmJURjZMMGFja1lXa3hfWjlvSnhZd1Zmb1c0RHE3STVlMmx2R1VjMHZra19pLVZGeE5CdjVFamp6bzRMWlVTdE9odi1uVzRaaXBvQ2tsMndfUDZNdUxKNUhuN1RENUdJTXBKcDZMUm0tdGJFZ3VyZEFSckJRc3ctTmlRRndmTWc?oc=5","date":"2023-07-31","type":"pipeline","source":"The Business Journals","summary":"Athenex assets sold in bankruptcy auction; top executives dismissed - The Business Journals","headline":"Athenex assets sold in bankruptcy auction; top executives dismissed","sentiment":"neutral"},{"date":"2023-07-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5NNU1iRzVKZFBhOHVxSHVKSlRZRURVMU93R0pVd3RPdFNvR25JVFJEeGpkdGFRYlJZWnljOXFHLXRxS0pHeFNSRFhoOXJXWUhyQmlkUFpQZHRIc19CcG85U0NnTWE3akk2cWNGVG5MWk5BcURDcmtVOA?oc=5","date":"2023-06-19","type":"pipeline","source":"Post Journal","summary":"Bankruptcy Final Blow To Athenex That Once Brought Hope - Post Journal","headline":"Bankruptcy Final Blow To Athenex That Once Brought Hope","sentiment":"neutral"},{"date":"2023-05-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPT3FNSHUtMm40cEo0ZWxEY0tsU3BVc0dqRVJtaW5kdjVZTk83TXBZWnZlSkRqZEY1U0RVcVAzMkRMV0xtelpYc3BvYWtFNXY1UUtZMWlQcFVFUGtub2dGMVlUejU0Y0Vvb0pKR1BESHJRZXotaldpbHRweGo3cVlsVThmTlBQTUxlbzZ5TDVYckdWVVpqV3dOSll4SUxIQlN6bVdSR3VzQWJYRmZabGRxWFVuYS01TzdK?oc=5","date":"2023-05-15","type":"deal","source":"Fierce Biotech","summary":"Athenex files for bankruptcy, seeks buyer for natural killer T-cell therapy unit - Fierce Biotech","headline":"Athenex files for bankruptcy, seeks buyer for natural killer T-cell therapy unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZkZicnZwWUtLRDJoQXY5Q1E0YkV6ZGFZc25FcVg4MUp4Uml0YUZfdVoxVTk1dGlHOVkxdU9LVXlZSWwwS19jQlR0VC1LV3FtV3VzMEtDbk1zRXQ3UTVDdy1wZnZ4bnRTTjdyWngybE9iZjdsWVNHc0tJS2NVaXBtVlRndWJEaUUxV0tJ?oc=5","date":"2023-05-14","type":"pipeline","source":"Yahoo Finance","summary":"Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process - Yahoo Finance","headline":"Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process","sentiment":"neutral"},{"date":"2023-05-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-04-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-03-20","type":"deal","source":"BioSpace","summary":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athen","headline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-03-20","type":"deal","source":"Business Wire","summary":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athen","headline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPenA3a19uSTB2ZUhma2J4VUtJQ0d3TEVzWGhjbkdkV3lycnR5SEJBX2dzVGNkWXNkSXMyWnVIT0NIOEViQWF6V3JKYnd4TUFmRWdVS0VqWVZjUFV6T1NCbHNoX1VRVE5YdzJEaWlmSG5maG9vMmtBbjV1U3lTdEVRTm9ZXzlFWXBGcUZrbHFMZkhrZjFlZzJMVmctWUFMR3JQWVJJRTFvZThDaEdDU2RTQzEtMl9qc1dNbTFTOFpQcFJJRlFXQUE?oc=5","date":"2023-01-03","type":"pipeline","source":"Fierce Pharma","summary":"Athenex to shutter New York production facility, lay off 92 workers - Fierce Pharma","headline":"Athenex to shutter New York production facility, lay off 92 workers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOLWNqdHZGa05OYXUxVXRXTm9WZGR2T0Q5bVBZdllJbUhmc3ZSZVVkNEZ1d1BIRE9yVUFVdk1zY2J6Y0NiNWR3TEczX0Q4N1ZQZVIxSjd5WUhoVTJ6RHBIQmx0azc0YnRLamhNQnp5c2Z0SHg1YU9uYzUxT0tIYWF4UllMQW5rRm90RXIxS2tlajBoN1EzSzVrYlVONUpjZWRNTVhoM3JZQjRSYTRNanppb0RzZm0?oc=5","date":"2022-01-12","type":"pipeline","source":"WKBW","summary":"Athenex enters into an agreement for ImmunityBio to takeover Dunkirk facility - WKBW","headline":"Athenex enters into an agreement for ImmunityBio to takeover Dunkirk facility","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":1,"phase_1":3,"discontinued":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":101229000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":101229000,"period":"2019-12-31"},{"value":89100000,"period":"2018-12-31"},{"value":38043000,"period":"2017-12-31"},{"value":13994000,"period":"2017-09-30"},{"value":4595000,"period":"2017-06-30"},{"value":4581000,"period":"2017-03-31"}],"grossProfit":26703000,"grossProfitHistory":[],"rdSpend":51758000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-103427000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":30437000,"cashHistory":[],"totalAssets":204055000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}